To investigate the role of ERK1/2 on chemoresistance, we knockdown ERK1/2 in PLK1-expressing CRC cells, subsequently treating them with 5-Fu for 48 h, and assessed cell viability. The gene discussed is MAPK3; the disease is colorectal carcinoma.